Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. - Wikidata - awgldk - TriplyDB

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

http://www.wikidata.org/entity/Q37384293

about

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan Targeting inflammation in pancreatic cancer: Clinical translation Genetics and biology of pancreatic ductal adenocarcinoma Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Pancreatic cancer: New hopes after first line treatment Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia.Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.Immune checkpoint inhibitors: a new frontier in bladder cancer.Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.Evolving treatment landscape for early and advanced pancreatic cancer.Second line treatment options for pancreatic cancer.MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.What treatment in 2017 for inoperable pancreatic cancers?Signaling pathways as therapeutic targets in biliary tract cancer.Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.Inflammation as a driver and vulnerability of KRAS mediated oncogenesis The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.Emerging protein kinase inhibitors for treating pancreatic cancer.Functio Laesa: Cancer Inflammation and Therapeutic Resistance.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.The role of stromal cancer-associated fibroblasts in pancreatic cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

P2860

Q26751368-531BB721-9EB1-4109-BB2A-660E571ED50F Q26751686-027972A2-9ACD-4B52-9A06-19F917617212 Q26765438-2F505BBB-B926-452D-B5DA-14E77B644404 Q28066268-333230E2-E47A-4769-9339-9F4F04763DE5 Q28067055-0FD1AF97-7DC2-4E27-A106-9D65DCB9AFD5 Q28069864-318A94F8-DB4F-40D2-9C24-5D6860F63BD0 Q28075540-94804DF7-C746-4282-ABC2-08577AEEEBC6 Q33438420-64D6C88A-6E16-4876-85E4-5039436A0C4C Q33704284-5F1BBDE1-F24D-46D6-B4F4-37D01E8A0D6A Q33727960-2AAA8AAE-A0C7-47E5-8EAD-2C792EA29B55 Q33880985-AC719D89-6591-43F9-97D2-B0A56B1137C4 Q36661995-1400ED1F-9A40-4E2C-9642-54A7ECC5581D Q37170527-0B58A9B7-F787-4C92-A8FD-FD18B3090994 Q37408595-60A3F9AE-2E6A-4CCA-B591-925AD9EA6FD1 Q37742975-03964099-8916-4335-9BE0-3A90E338395B Q38612706-F1593289-1246-4A70-A982-817BC3312BA5 Q38620187-D6AE4750-ED68-4288-B956-C0C8A9E1CBB3 Q38624806-DF3099E1-D299-4920-8265-57EBED5348D3 Q38640398-64793518-D045-4F5C-98FC-45CCB1AAC829 Q38674196-00EC66FC-0F64-4126-8A74-EB0CF4F804C8 Q38689025-10746945-E5E5-484E-9393-968F44F75B66 Q38747573-F84D985C-7051-4C69-82EA-6BE01518849F Q38777938-47F8D242-2292-4193-94A4-F16B60B75E6F Q38797818-62D7914D-B017-4CF6-B71F-4FAFCC9EE78F Q38839108-BBBA0DA7-1BE8-44E7-810E-ADFC67CF916B Q38864070-3E2A5FC1-E396-47BF-9525-0FE8FEA6B9A7 Q38879975-95BD58EA-E30B-4A27-B119-545E2A57AEE0 Q39039925-471F0CB8-95E3-44CD-AE8C-D6915E2B4E2B Q39158411-8A582446-52B4-427E-89FC-59FE4987EBC9 Q39172861-A2EF1851-4CFA-419B-9A23-F2EDE8847A7A Q39204274-EC08A007-0759-4F3D-B8EA-B3EC86BFB79D Q39205210-AA532AC2-8E9A-4D2E-BAB7-EE0A5C5B530C Q39390859-AE0C662D-E886-4CC9-BE77-9D341116E89C Q39429983-772068FD-118B-442F-9BC3-7E70DC3D5EF6 Q39453577-7A013FC6-A790-44FF-B518-C249DDB108EC Q41865091-F8400112-9AF8-4153-B990-D2044998C278 Q47126909-89FB56BC-FC3F-48A2-B574-88FAF622BAEB Q47148643-56073DB2-8233-4A26-8BD0-D4B840FBF92D Q47206128-EFED54C3-8B2B-4212-B0E2-2DF1AC8A0865 Q47400640-B145E344-3735-4B1F-8B37-E429E1C30B55

P2860

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

http://www.wikidata.org/entity/Q37384293

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@en

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@nl

type

label

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@en

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@nl

prefLabel

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@en

Randomized, Double-Blind, Phas ...... y With Gemcitabine Has Failed.

@nl

P1433

Q37384293-C2BA9C08-067C-4D93-80C0-DA27E640F69A

P1476

Q37384293-052620B3-EED5-4A8E-9670-246941465A1D

P2093

Q37384293-1C3919CB-07C2-4FB5-BAD3-9FE59FC6B5ED

Q37384293-251CF14C-4DDF-48DB-8170-55D9E7B1762F

Q37384293-2797157A-5752-42FF-9E7A-11E70B318058

Q37384293-2DBDBBCF-9BEA-4328-8917-5B9F7605C22E

Q37384293-54D52B67-5C01-4208-8567-23202608CA72

Q37384293-6005F517-F513-4AF3-9E84-16C90C38BA9C

Q37384293-86576C06-E601-48C9-8EAB-5E1ABF0A1C3C

Q37384293-8E3A8F10-42FB-463E-AF24-66BA5E2F3655

Q37384293-A09A7950-9BD5-4517-A26B-F00DE7D5D72C

Q37384293-AC6B189C-B711-4E47-A469-AB0A4D668B45

P2860

Q37384293-00DCDC5E-BCA1-4C67-9932-67DC8ED2F5DA

Q37384293-06084E57-FA0D-4052-94F1-407E66BC4091

Q37384293-09F361E5-9A6E-48C6-89AF-DE12D3ED87F9

Q37384293-0E5E1F24-A7F2-4A94-B0DC-7B51343F9A79

Q37384293-122368B5-5367-4D07-8BA5-5915AA943287

Q37384293-186A0B37-F9B5-4B82-96BA-3A91E379A740

Q37384293-1D96FB94-3BC3-48E3-8B29-B458B1A1A682

Q37384293-2236FCCB-90E6-45FC-8D56-26D8020904BB

Q37384293-24BA9EE0-AC2C-4921-8247-F20F67ABC802

Q37384293-28AD8DBE-92A4-490A-85F0-A40CC104EF8E

P304

Q37384293-C7B2EB9B-B9FB-41F7-A763-FB69AC7DE57F

P31

Q37384293-C3BB65D2-A63A-4D9F-8449-3ECAAAE9BE37

P356

Q37384293-ABA5C558-977C-4B66-8A54-8428D5878C18

P407

Q37384293-DB0B94ED-E98D-4FC2-865F-AFE9806A3DEA

P433

Q37384293-BDE0DD72-6F6F-42FC-9F9A-DE29D76B3BD8

P478

Q37384293-2AE09C87-1589-411A-A152-467EBEE96BD1

P50

Q37384293-0E912B6E-E06E-411D-8F48-4D7CDC4888EF

P577

Q37384293-3E30AE96-9189-4FDD-8083-EC5E0C661F49

P698

Q37384293-1B5CC5B1-90E1-4F67-B00C-A9443448C009

P921

Q37384293-26DF23A1-6349-42A6-95F0-9FA1A0921CFF

P932

Q37384293-7B1A3C19-C5F5-4421-8EF4-02387707F62D

P356

JCO.2015.61.4578

P1433

Journal of Clinical Oncology

P1476

Randomized, Double-Blind, Phas ...... py With Gemcitabine Has Failed

@en

P2093

Deborah S Hunter

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

J Marc Pipas

http://www.w3.org/2001/XMLSchema#string

J Thaddeus Beck

http://www.w3.org/2001/XMLSchema#string

Jason Clark

http://www.w3.org/2001/XMLSchema#string

Johanna C Bendell

http://www.w3.org/2001/XMLSchema#string

John J Nemunaitis

http://www.w3.org/2001/XMLSchema#string

Lance Leopold

http://www.w3.org/2001/XMLSchema#string

Philip J Stella

http://www.w3.org/2001/XMLSchema#string

Richard S Levy

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

The regulation of inflammation by interferons and their STATs

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

STATs in cancer inflammation and immunity: a leading role for STAT3

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice.

P304

4039-4047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.61.4578

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26351344

http://www.w3.org/2001/XMLSchema#string

P921

P932

5089161

http://www.w3.org/2001/XMLSchema#string